Trial · NCT04116047
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047, Phase 3, Active not recruiting, University of Birmingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC). Trials, record NCT04116047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04116047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
- NCT number
- NCT04116047
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 785 participants, estimated
- Lead sponsor
- University of Birmingham
- Conditions
- Oropharyngeal Cancer
- Interventions
- Cisplatin, Durvalumab, Radiotherapy
- First posted
- 2019-10-04
- Last updated
- 2026-05-07
- Other registries' IDs
- eudract:2014-003389-26, isrctn:ISRCTN41478539
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient Overall survival (OS) | from randomisation until date of death from any cause (follow-up until 8 years post-treatment) | defined as the interval in whole days between date of randomisation and date of death from any cause |
| Primary | Patient Event Free Survival (EFS) | From randomisation until date of progression/persistence/recurrence/death (follow-up until 8 years post-treatment) | defined as the interval in whole days between date of randomisation until date of progression/persistence/recurrence/death |
| Secondary | Number of Acute (<3 months post-treatment) toxicity events experienced | From date of randomisation until 2 year follow-up | Total number of acute (\<3 months post-treatment) severe (grade 3-5) toxicity events experienced. Adverse events will be collected post-treatment and graded according to Common Terminology Criteria for Adverse Events (CTCAE). |
| Secondary | Number of late (up to 2 years post-treatment) toxicity events experienced using CTCAE | From date of randomisation until 2 year follow-up | Severe (grade 3-5) adverse events will be collected up to 2 years post randomisation, these events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and version 3.0 for scoring mucositis. |
| Secondary | Number of late (up to 2 years post-treatment) toxicity events experienced using RTOG | From date of randomisation until 2 year follow-up | Late and severe toxicity events at 2 years post randomisation,will be collected and graded using Radiation Therapy Oncology Group (RTOG) Radiation Morbidity Scoring Criteria |
| Secondary | Head and neck specific quality of life at 2 years post-randomisation using EORTC C30 | From date of randomisation until 2 year follow-up | Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) C30 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment |
| Secondary | Head and neck specific Quality of Life at 2 years post-randomisation | From date of randomisation until 2 year follow-up | Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) H\&N35 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment |
| Secondary | Swallowing outcomes assessed using MDADI Questionnaire at 24 months post-chemoradiotherapy | From date of randomisation until 2 year follow-up | Patients will complete the M.D. Anderson Dysphagia Inventory (MDADI) Questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment |
| Secondary | Levels of Percutaneous Endoscopic Gastrostomy (PEG) use | From date of randomisation until 2 year follow-up | PEG use will be assessed at baseline, throughout treatment and during 2 year follow-up period |
| Secondary | Cost effectiveness of treatment as assessed using EuroQol Group (EQ-5D) questionnaire | From date of randomisation until 2 year follow-up | Patients will complete the EuroQol Group (EQ-5D) questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04116047
GET https://conductscience.org/api/trials/v1/NCT04116047/registered